Published in Medical Letter on the CDC and FDA, December 28th, 2003
The goal of the two contracts is to develop new forensic tools that will increase the ability of investigators to identify individuals using DNA samples that have degraded and therefore contain a limited amount of genetic material. Work on both of these contracts is being undertaken in Orchid Cellmark's Dallas, Texas, facility and is expected to be completed in about 1 year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA